Porton Pharma is expanding its operations in Europe by building a new cGMP state of the art facility inside the Life Science Park Mengeš, Slovenia. The new site will allow Porton to develop and manufacture APIs and HPAPIs in Europe relying on two new R&D buildings equipped with several labs and cGMP kilo labs, a new cGMP pilot plant and a new full-scale cGMP manufacturing facility. The new site will employ more than 300 people over time.